Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Adherens junction (mmu04520)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
AK134499
KLA  ATP  ATP+KLA
 AK134499 11 days embryo head cDNA, RIKEN full-length enriched library, clone:6230419C23 product:unclassifiable, full insert sequence [AK134499] KLA .97 1.04 .99 1.01 .93 1.08 1.21
ATP .97 1.02 .97 1.13 1.01 .98 1.06
KLA/ATP .95 .98 1.00 .95 1.00 .98 1.02
Acp1
KLA  ATP  ATP+KLA
 NM_001110239 acid phosphatase 1, soluble (Acp1), transcript variant 1, mRNA [NM_001110239] KLA 1.15 1.18 1.12 1.18 1.14 1.10 1.18
ATP .94 1.01 1.12 1.23 .90 .68 .98
KLA/ATP 1.10 1.24 1.20 1.33 .94 .82 .99
Actb
KLA  ATP  ATP+KLA
 BC016624 cDNA clone IMAGE:4501052 [BC016624] KLA 1.20 1.20 1.19 1.73 1.83 2.52 1.70
ATP 1.04 1.01 1.03 .92 1.07 .66 .91
KLA/ATP 1.34 1.40 1.69 1.28 1.27 1.19 1.06
Actb
KLA  ATP  ATP+KLA
 NM_007393 actin, beta, cytoplasmic (Actb), mRNA [NM_007393] KLA 1.58 1.64 1.59 2.02 2.03 3.04 1.75
ATP 1.00 .95 1.26 1.18 1.33 .86 .91
KLA/ATP 1.52 1.75 2.42 1.92 2.17 1.54 1.28
Actg1
KLA  ATP  ATP+KLA
 NM_009609 actin, gamma, cytoplasmic 1 (Actg1), mRNA [NM_009609] KLA 1.02 1.03 1.34 1.07 1.49 1.58 .71
ATP 1.07 1.24 .76 .76 .63 .46 .78
KLA/ATP 1.20 1.30 .75 .82 .60 .53 .55
Actn1
KLA  ATP  ATP+KLA
 NM_134156 actinin, alpha 1 (Actn1), mRNA [NM_134156] KLA 1.33 1.42 1.46 1.16 1.18 .69 .54
ATP 1.06 1.13 .67 1.15 .95 .99 1.46
KLA/ATP 1.66 1.64 .81 1.55 .82 .78 .76
Actn2
KLA  ATP  ATP+KLA
 NM_033268 actinin alpha 2 (Actn2), mRNA [NM_033268] KLA 1.03 .94 1.02 1.05 1.02 1.06 1.11
ATP 1.04 .98 1.07 .99 1.10 1.03 1.02
KLA/ATP 1.06 1.03 .99 1.08 1.01 1.05 .98
Actn3
KLA  ATP  ATP+KLA
 NM_013456 actinin alpha 3 (Actn3), mRNA [NM_013456] KLA .97 .98 .98 .94 1.03 .96 1.07
ATP .95 .95 1.02 .98 .94 .95 1.01
KLA/ATP 1.05 1.03 .94 1.03 1.03 1.00 .95
Actn4
KLA  ATP  ATP+KLA
 NM_021895 actinin alpha 4 (Actn4), mRNA [NM_021895] KLA .78 .77 .75 .74 .58 .51 .65
ATP 1.03 1.03 1.21 1.14 1.50 1.30 1.09
KLA/ATP .78 .85 .96 .84 1.09 1.12 .97
BI646741
KLA  ATP  ATP+KLA
 BI646741 gb|BI646741 603279769F1 NCI_CGAP_Mam3 Mus musculus cDNA clone IMAGE:5320025 5, mRNA sequence [BI646741] KLA .55 .54 .47 .54 .65 1.09 1.60
ATP 1.04 .99 .93 1.08 2.49 .79 .88
KLA/ATP .54 .49 .54 .60 1.21 .97 1.54
Baiap2
KLA  ATP  ATP+KLA
 NM_001037754 brain-specific angiogenesis inhibitor 1-associated protein 2 (Baiap2), transcript variant 3, mRNA [NM_001037754] KLA .70 .70 .71 .66 .63 .78 .60
ATP 1.03 1.19 1.30 3.72 4.02 2.43 2.11
KLA/ATP .71 .76 .84 2.81 4.32 4.09 2.11
Baiap2
KLA  ATP  ATP+KLA
 NM_130862 brain-specific angiogenesis inhibitor 1-associated protein 2 (Baiap2), transcript variant 2, mRNA [NM_130862] KLA .59 .59 .55 .56 .47 .55 .56
ATP .88 .92 1.04 1.12 .62 .98 2.48
KLA/ATP .57 .56 .63 .72 .63 1.00 1.41
CF586908
KLA  ATP  ATP+KLA
 CF586908 gb|AGENCOURT_8784932_updated NIH_MGC_140 Mus musculus cDNA clone IMAGE:6436450 5, mRNA sequence [CF586908] KLA 1.01 1.01 1.01 .98 1.04 1.04 1.05
ATP 1.03 .94 1.02 1.07 1.07 1.01 1.07
KLA/ATP .99 1.00 1.04 1.11 1.14 1.04 1.00
Cdc42
KLA  ATP  ATP+KLA
 NM_009861 cell division cycle 42 homolog (S. cerevisiae) (Cdc42), mRNA [NM_009861] KLA 1.04 1.01 1.02 1.04 1.12 1.21 1.12
ATP 1.07 1.10 1.04 1.06 1.02 .95 1.14
KLA/ATP .94 1.04 1.01 .97 .95 1.02 1.25
Cdh1
KLA  ATP  ATP+KLA
 NM_009864 cadherin 1 (Cdh1), mRNA [NM_009864] KLA 1.03 1.03 .99 .94 .95 .97 .99
ATP 1.04 1.06 1.06 .96 .99 1.07 .95
KLA/ATP 1.02 1.07 1.00 .90 .93 .94 .98
Crebbp
KLA  ATP  ATP+KLA
 AK048818 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230072N21 product:hypothetical protein, full insert sequence [AK048818] KLA 1.44 1.19 1.26 1.25 1.25 1.36 1.24
ATP .98 .90 1.04 1.11 1.95 2.72 1.51
KLA/ATP 1.17 1.27 1.45 1.28 1.98 2.80 2.52
Crebbp
KLA  ATP  ATP+KLA
 NM_001025432 CREB binding protein (Crebbp), mRNA [NM_001025432] KLA .97 1.01 .98 1.06 1.05 .99 1.07
ATP 1.07 1.05 .96 1.01 1.15 1.14 1.00
KLA/ATP 1.01 .97 .97 1.00 1.03 1.23 1.13
Crebbp
KLA  ATP  ATP+KLA
 S66385 gb|CREB-binding protein [mice, brain, mRNA Partial, 7326 nt]. [S66385] KLA 1.00 .98 1.08 .98 1.04 1.07 1.08
ATP .99 .98 .99 1.09 1.13 1.08 1.05
KLA/ATP 1.06 1.00 1.05 1.03 1.02 1.14 1.11
Csnk2a1
KLA  ATP  ATP+KLA
 NM_007788 casein kinase 2, alpha 1 polypeptide (Csnk2a1), mRNA [NM_007788] KLA 1.36 1.39 1.19 1.34 1.32 1.74 1.86
ATP .92 .88 1.13 .86 1.12 2.50 1.99
KLA/ATP 1.19 1.24 1.35 1.03 1.16 2.09 2.88
Csnk2a2
KLA  ATP  ATP+KLA
 NM_009974 casein kinase 2, alpha prime polypeptide (Csnk2a2), mRNA [NM_009974] KLA 1.46 1.53 1.70 1.47 1.32 1.32 1.17
ATP 1.00 1.11 1.17 1.33 1.71 2.03 1.06
KLA/ATP 1.58 1.67 1.69 2.00 2.20 2.44 1.68
Csnk2b
KLA  ATP  ATP+KLA
 NM_009975 casein kinase 2, beta polypeptide (Csnk2b), mRNA [NM_009975] KLA 1.19 1.10 1.12 1.13 1.20 1.28 1.25
ATP 1.12 1.03 1.04 1.07 1.20 1.27 1.09
KLA/ATP 1.15 1.20 1.25 1.13 1.44 1.34 1.35
Ctnna1
KLA  ATP  ATP+KLA
 AK008121 adult male small intestine cDNA, RIKEN full-length enriched library, clone:2010005H04 product:unclassifiable, full insert sequence. [AK008121] KLA .82 .76 .72 .81 .94 .74 .80
ATP 1.08 1.01 .51 .57 2.45 1.25 .95
KLA/ATP .91 .82 .76 .58 1.58 1.01 .92
Ctnna1
KLA  ATP  ATP+KLA
 NM_009818 catenin (cadherin associated protein), alpha 1 (Ctnna1), mRNA [NM_009818] KLA .97 .91 1.06 .84 .75 .52 .56
ATP 1.09 1.14 1.00 .86 .80 .98 .83
KLA/ATP 1.02 1.07 .90 .80 .66 .59 .57
Ctnna2
KLA  ATP  ATP+KLA
 AK035033 12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN full-length enriched library, clone:9430076K22 product:hypothetical Vinculin and alpha-catenin containing protein, full insert sequence [AK035033] KLA 1.05 1.11 1.12 1.05 1.02 1.04 1.19
ATP .99 .97 1.00 1.05 1.02 1.05 1.03
KLA/ATP 1.11 1.06 1.01 1.12 1.06 1.02 1.03
Ctnna3
KLA  ATP  ATP+KLA
 AK029664 adult male testis cDNA, RIKEN full-length enriched library, clone:4930438F12 product:unclassifiable, full insert sequence. [AK029664] KLA 1.03 1.06 .99 1.05 .95 1.01 1.04
ATP 1.03 1.05 1.02 1.04 .99 1.03 1.05
KLA/ATP 1.01 1.00 .99 1.01 1.00 .98 1.05
Ctnna3
KLA  ATP  ATP+KLA
 NM_177612 catenin (cadherin associated protein), alpha 3 (Ctnna3), mRNA [NM_177612] KLA 1.01 1.06 .98 1.04 1.03 1.04 1.07
ATP .96 1.02 .94 1.11 1.02 1.09 .91
KLA/ATP 1.01 .94 .94 1.10 1.10 1.04 1.04
Ctnnb1
KLA  ATP  ATP+KLA
 AK020013 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830416C23 product:catenin beta, full insert sequence. [AK020013] KLA 1.06 1.15 1.00 1.06 1.27 1.14 1.03
ATP .85 .57 1.74 3.36 4.13 2.19 1.55
KLA/ATP 1.12 .87 2.47 3.61 3.79 2.21 2.06
Ctnnb1
KLA  ATP  ATP+KLA
 NM_007614 catenin (cadherin associated protein), beta 1 (Ctnnb1), mRNA [NM_007614] KLA 1.02 1.07 1.13 1.03 1.04 .93 .96
ATP 1.12 1.14 .75 .77 .73 .72 1.52
KLA/ATP 1.18 1.17 .77 .85 .60 .59 1.35
Ctnnd1
KLA  ATP  ATP+KLA
 NM_007615 catenin (cadherin associated protein), delta 1 (Ctnnd1), transcript variant 1, mRNA [NM_007615] KLA 1.94 1.92 2.21 1.62 1.28 1.01 1.10
ATP 1.15 .87 .49 .55 .71 1.90 2.20
KLA/ATP 2.22 1.83 .80 .75 .58 1.20 2.61
Egfr
KLA  ATP  ATP+KLA
 NM_007912 epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] KLA 1.10 1.07 1.14 1.11 1.08 1.03 .90
ATP .99 1.00 1.04 .98 .97 1.15 1.14
KLA/ATP 1.07 1.10 1.16 1.08 1.01 .97 .94
Egfr
KLA  ATP  ATP+KLA
 NM_207655 epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] KLA 1.57 1.44 1.47 1.31 .96 .92 .76
ATP .97 .93 1.10 1.00 1.41 2.97 .86
KLA/ATP 1.44 1.50 1.61 1.30 1.14 1.21 .82
Ep300
KLA  ATP  ATP+KLA
 AK042627 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730011L11 product:P300 TRANSCRIPTION COACTIVATOR (FRAGMENT) homolog [Mus sp], full insert sequence. [AK042627] KLA 1.02 .95 .92 1.04 1.01 1.00 1.05
ATP 1.06 .89 .88 .89 1.00 .90 1.07
KLA/ATP 1.10 1.02 .87 .91 1.04 .97 .98
Ep300
KLA  ATP  ATP+KLA
 NM_177821 E1A binding protein p300 (Ep300), mRNA [NM_177821] KLA 1.61 1.26 1.57 1.38 1.78 1.41 1.40
ATP 1.34 1.60 1.11 1.08 1.16 1.05 1.15
KLA/ATP 1.86 1.94 1.18 1.56 1.71 1.42 2.05
Erbb2
KLA  ATP  ATP+KLA
 NM_001003817 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (Erbb2), mRNA [NM_001003817] KLA 1.01 1.00 .98 1.01 .98 .99 .97
ATP .99 1.00 1.00 1.00 .96 .98 .99
KLA/ATP 1.00 1.01 1.01 1.02 .96 .98 .97
Farp2
KLA  ATP  ATP+KLA
 NM_145519 FERM, RhoGEF and pleckstrin domain protein 2 (Farp2), mRNA [NM_145519] KLA .94 .99 .92 .93 1.10 1.22 1.40
ATP 1.01 1.03 .85 .91 .76 .78 1.09
KLA/ATP 1.05 .93 .80 .83 .88 .98 1.96
Fert2
KLA  ATP  ATP+KLA
 NM_001037997 fer (fms/fps related) protein kinase, testis specific 2 (Fert2), transcript variant 1, mRNA [NM_001037997] KLA .90 1.02 .84 1.02 1.06 1.11 1.15
ATP 1.04 .99 1.01 .93 .78 .63 1.01
KLA/ATP .95 .95 .97 .99 .91 .67 .91
Fert2
KLA  ATP  ATP+KLA
 NM_008000 fer (fms/fps related) protein kinase, testis specific 2 (Fert2), transcript variant 2, mRNA [NM_008000] KLA .93 1.01 1.05 1.04 1.18 1.29 1.24
ATP 1.01 1.06 1.01 1.12 .67 .54 1.18
KLA/ATP 1.01 1.09 .89 1.06 .65 .67 1.12
Fgfr1
KLA  ATP  ATP+KLA
 M28998 gb|Mouse basic fibroblast growth factor receptor (bFGF-R) mRNA, complete cds. [M28998] KLA .82 .79 .73 .66 .50 .55 .65
ATP 1.01 1.08 .86 .90 1.29 1.24 1.52
KLA/ATP .85 .82 .71 .71 .63 .80 .85
Fgfr1
KLA  ATP  ATP+KLA
 NM_010206 fibroblast growth factor receptor 1 (Fgfr1), transcript variant 1, mRNA [NM_010206] KLA .92 .86 .73 .82 .79 .85 .84
ATP 1.01 1.06 .92 .92 1.18 1.02 1.22
KLA/ATP .83 .83 .79 .76 .83 .83 .92
Fyn
KLA  ATP  ATP+KLA
 U70324 Fyn(T) (L-fyn(T)) mRNA, complete cds. [U70324] KLA 1.23 1.27 1.31 1.27 1.31 .87 .48
ATP .88 .71 .66 .75 .90 1.28 .51
KLA/ATP 1.12 1.01 .94 .84 1.25 1.51 .53
Igf1r
KLA  ATP  ATP+KLA
 NM_010513 insulin-like growth factor I receptor (Igf1r), mRNA [NM_010513] KLA 1.32 1.32 1.08 .91 .55 .48 .45
ATP 1.03 1.06 1.06 1.29 1.31 1.45 .47
KLA/ATP 1.30 1.37 1.11 1.00 .93 1.02 .45
Insr
KLA  ATP  ATP+KLA
 NM_010568 insulin receptor (Insr), mRNA [NM_010568] KLA .75 .81 .77 .69 .69 .69 .83
ATP 1.07 1.06 .88 .79 .73 .77 .83
KLA/ATP .80 .80 .72 .71 .64 .64 .70
Iqgap1
KLA  ATP  ATP+KLA
 NM_016721 IQ motif containing GTPase activating protein 1 (Iqgap1), mRNA [NM_016721] KLA 1.02 1.12 1.02 .85 .93 .86 .84
ATP 1.08 1.17 .93 1.22 .89 .68 1.00
KLA/ATP 1.17 1.13 .76 1.00 .67 .69 1.08
LOC10004
6483
KLA  ATP  ATP+KLA
 XM_001476285 ref|PREDICTED: Mus musculus similar to casein kinase II, alpha prime subunit (LOC100046483), mRNA [XM_001476285] KLA .97 .94 .94 .88 .84 .76 .88
ATP 1.06 1.04 .89 .82 .87 .70 .56
KLA/ATP 1.03 1.00 .88 .75 .73 .66 .43
Lef1
KLA  ATP  ATP+KLA
 NM_010703 lymphoid enhancer binding factor 1 (Lef1), mRNA [NM_010703] KLA 1.00 1.05 1.00 1.05 1.01 1.07 1.07
ATP .96 .98 1.03 1.09 .99 1.04 1.00
KLA/ATP 1.02 .98 .95 1.08 1.02 1.16 1.08
Lmo7
KLA  ATP  ATP+KLA
 AK047836 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130003G01 product:similar to LIM protein [Homo sapiens], full insert sequence. [AK047836] KLA 1.05 .96 1.03 .98 .96 .97 1.00
ATP 1.00 1.01 1.01 1.07 1.01 .97 1.05
KLA/ATP .99 1.00 1.02 1.00 .97 1.09 .99
Lmo7
KLA  ATP  ATP+KLA
 AK053129 0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030010D13 product:inferred: unnamed protein product {Homo sapiens}, full insert sequence. [AK053129] KLA .95 1.02 .97 .95 .99 1.11 1.13
ATP .98 .93 1.07 1.08 1.01 1.07 1.04
KLA/ATP 1.06 1.04 1.00 1.09 1.11 1.10 .94
Lmo7
KLA  ATP  ATP+KLA
 NM_201529 LIM domain only 7 (Lmo7), mRNA [NM_201529] KLA .98 .89 .94 .84 .92 .85 .94
ATP .96 1.00 .98 1.03 1.01 1.04 .93
KLA/ATP .93 .90 .97 .88 .97 .92 .98
Map3k7
KLA  ATP  ATP+KLA
 NM_172688 mitogen-activated protein kinase kinase kinase 7 (Map3k7), mRNA [NM_172688] KLA 1.48 1.49 1.51 1.24 1.21 1.19 1.61
ATP 1.10 1.16 1.03 1.03 1.12 1.61 1.61
KLA/ATP 1.43 1.56 1.05 1.15 .85 1.48 1.76
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Met
KLA  ATP  ATP+KLA
 NM_008591 met proto-oncogene (Met), mRNA [NM_008591] KLA 3.56 3.71 3.68 3.79 4.24 5.89 6.95
ATP .98 .96 1.16 1.21 3.32 12.98 6.60
KLA/ATP 3.75 3.80 3.58 3.28 3.69 4.27 14.22
Mllt4
KLA  ATP  ATP+KLA
 NM_010806 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 4 (Mllt4), mRNA [NM_010806] KLA .70 .66 .57 .68 .70 .66 .82
ATP 1.03 1.01 1.05 .96 .76 .91 1.15
KLA/ATP .65 .68 .66 .54 .82 1.14 1.10
Mm.23692
KLA  ATP  ATP+KLA
 164565453 Unknown KLA .83 .77 .72 .65 .61 .75 .80
ATP .77 .94 1.03 .63 .61 .74 .59
KLA/ATP .58 .78 .77 .52 .51 .56 .30
Mm.27574
2
KLA  ATP  ATP+KLA
 112983655 Unknown KLA 1.35 1.16 .94 .85 .45 .33 .31
ATP .90 .86 1.17 1.09 1.18 1.21 .38
KLA/ATP 1.12 1.22 1.19 .91 .90 .83 .33
Mm.27604
2
KLA  ATP  ATP+KLA
 18702319 Unknown KLA .81 .72 .70 .70 .54 .54 .67
ATP .90 .95 1.17 1.15 1.35 1.32 1.13
KLA/ATP .70 .78 .89 .83 1.09 1.13 .97
Mm.27791
6
KLA  ATP  ATP+KLA
 133505844 Unknown KLA .72 .68 .80 1.17 1.52 1.33 1.19
ATP .85 .76 .85 .58 1.10 1.47 .53
KLA/ATP .61 .62 .79 .68 1.96 1.74 .48
Mm.31180
9
KLA  ATP  ATP+KLA
 6679562 Unknown KLA 1.00 1.03 1.18 1.08 1.06 1.28 6.03
ATP 1.03 1.00 1.03 1.08 .87 .99 1.15
KLA/ATP 1.07 1.12 1.00 1.12 1.03 1.06 1.17
Mm.33509
6
KLA  ATP  ATP+KLA
 40254533 Unknown KLA .68 .70 .59 .64 .45 .52 .51
ATP .99 1.04 1.00 .80 1.26 1.55 .86
KLA/ATP .68 .74 .66 .70 1.21 1.77 .77
Mm.35983
1
KLA  ATP  ATP+KLA
 159032061 Unknown KLA 1.02 .93 .95 .94 1.01 .97 1.11
ATP .97 1.01 1.07 1.03 .93 1.03 1.02
KLA/ATP .94 .91 .99 .97 .97 .98 .91
Mm.4341
KLA  ATP  ATP+KLA
 31982076 Unknown KLA 15.21 12.82 10.30 10.79 6.76 4.53 2.96
ATP 1.06 .90 .81 .46 .58 1.71 .85
KLA/ATP 11.00 11.87 16.67 9.82 6.57 3.88 2.71
Mm.45680
7
KLA  ATP  ATP+KLA
 157951728 Unknown KLA 1.00 1.02 1.05 .97 .99 .96 1.05
ATP 1.13 .98 1.00 1.06 1.02 .94 .98
KLA/ATP 1.11 .96 1.08 1.01 .99 1.01 .98
Nlk
KLA  ATP  ATP+KLA
 NM_008702 nemo like kinase (Nlk), mRNA [NM_008702] KLA .71 .70 .64 .71 .78 .95 .94
ATP .91 .89 .95 .70 .45 .64 1.05
KLA/ATP .61 .66 .84 .54 .53 .58 .79
Pard3
KLA  ATP  ATP+KLA
 AK076429 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4832405A21 product:par-3 (partitioning defective 3) homolog (C. elegans), full insert sequence. [AK076429] KLA .96 .96 1.03 .96 1.03 .99 1.19
ATP .97 .92 1.09 .99 1.00 1.03 .94
KLA/ATP .97 1.01 .97 1.05 .98 .92 1.04
Pard3
KLA  ATP  ATP+KLA
 NM_001013580 par-3 (partitioning defective 3) homolog (C. elegans) (Pard3), transcript variant 2, mRNA [NM_001013580] KLA 1.02 .99 1.03 .97 1.00 .97 1.04
ATP .93 1.02 .98 .95 1.02 1.02 .98
KLA/ATP 1.04 .98 1.01 .99 .96 .91 .95
Pard3
KLA  ATP  ATP+KLA
 NM_001013581 par-3 (partitioning defective 3) homolog (C. elegans) (Pard3), transcript variant 1, mRNA [NM_001013581] KLA .99 1.06 1.02 1.02 1.00 .98 .95
ATP .91 1.05 1.06 .99 1.04 .89 .99
KLA/ATP .98 .97 1.09 .97 1.01 .98 1.00
Pard3
KLA  ATP  ATP+KLA
 NM_001122850 par-3 (partitioning defective 3) homolog (C. elegans) (Pard3), transcript variant 4, mRNA [NM_001122850] KLA 1.01 .95 1.00 1.01 1.07 .91 .99
ATP 1.00 1.01 .98 .94 1.04 .98 1.00
KLA/ATP .99 .99 1.04 1.04 1.04 1.01 1.03
Pard3
KLA  ATP  ATP+KLA
 NM_033620 par-3 (partitioning defective 3) homolog (C. elegans) (Pard3), transcript variant 3, mRNA [NM_033620] KLA .92 .93 .97 .96 1.00 .99 1.02
ATP 1.08 1.03 .93 .92 .99 .97 1.00
KLA/ATP .99 1.03 1.02 1.05 .96 1.06 1.03
Ptpn1
KLA  ATP  ATP+KLA
 NM_011201 protein tyrosine phosphatase, non-receptor type 1 (Ptpn1), mRNA [NM_011201] KLA .91 .93 1.16 1.45 2.07 1.55 1.63
ATP 1.03 1.01 .83 .70 1.31 1.65 .92
KLA/ATP .93 .93 .98 1.02 1.99 2.02 1.03
Ptpn6
KLA  ATP  ATP+KLA
 NM_001077705 protein tyrosine phosphatase, non-receptor type 6 (Ptpn6), transcript variant 2, mRNA [NM_001077705] KLA .87 .90 1.03 1.05 1.83 1.96 2.34
ATP 1.06 1.09 .94 1.08 .51 .34 1.04
KLA/ATP .98 .93 .71 .95 .67 .64 1.44
Ptpn6
KLA  ATP  ATP+KLA
 NM_013545 protein tyrosine phosphatase, non-receptor type 6 (Ptpn6), transcript variant 1, mRNA [NM_013545] KLA 1.24 1.20 1.46 1.42 2.43 2.27 2.10
ATP 1.18 1.20 1.10 1.49 .80 .58 1.09
KLA/ATP 1.36 1.42 1.27 1.66 1.12 .87 1.46
Ptpn6
KLA  ATP  ATP+KLA
 S63763 gb|me/Hcph (mev)=viable motheaten/hematopoietic cell protein-tyrosine phosphatase {insertion} [mice, mRNA Partial Mutant, 120 nt]. [S63763] KLA 1.06 1.03 1.12 1.14 1.11 1.01 1.09
ATP 1.03 .97 .96 .90 .89 1.17 1.76
KLA/ATP 1.07 1.00 1.03 .98 1.00 1.29 1.44
Ptprb
KLA  ATP  ATP+KLA
 NM_029928 protein tyrosine phosphatase, receptor type, B (Ptprb), mRNA [NM_029928] KLA 1.07 1.01 .99 1.07 1.02 1.02 1.03
ATP 1.00 1.01 .99 1.06 .99 .97 .97
KLA/ATP 1.07 .99 1.03 1.00 1.00 1.07 1.01
Ptprf
KLA  ATP  ATP+KLA
 NM_011213 protein tyrosine phosphatase, receptor type, F (Ptprf), mRNA [NM_011213] KLA 1.28 1.42 1.29 1.27 1.17 1.19 1.27
ATP 1.09 1.11 1.27 1.29 1.53 2.24 2.95
KLA/ATP 1.31 1.42 1.28 1.33 1.25 1.50 1.60
Ptprj
KLA  ATP  ATP+KLA
 NM_008982 protein tyrosine phosphatase, receptor type, J (Ptprj), mRNA [NM_008982] KLA 3.97 3.84 4.14 4.26 4.28 3.68 3.13
ATP 1.02 1.11 1.10 1.34 1.52 2.87 2.16
KLA/ATP 3.88 4.18 3.55 4.01 2.69 2.84 4.22
Ptprm
KLA  ATP  ATP+KLA
 NM_008984 protein tyrosine phosphatase, receptor type, M (Ptprm), mRNA [NM_008984] KLA .99 1.08 1.01 1.15 1.02 1.26 5.69
ATP .99 1.01 1.05 .95 .96 .96 1.11
KLA/ATP .99 1.09 1.11 1.03 .95 1.04 1.29
Pvrl1
KLA  ATP  ATP+KLA
 NM_021424 poliovirus receptor-related 1 (Pvrl1), mRNA [NM_021424] KLA .69 .68 .57 .61 .46 .47 .49
ATP .97 .99 .94 .78 1.28 1.54 .89
KLA/ATP .70 .66 .69 .63 1.22 1.72 .81
Pvrl3
KLA  ATP  ATP+KLA
 NM_021495 poliovirus receptor-related 3 (Pvrl3), transcript variant alpha, mRNA [NM_021495] KLA 1.27 1.25 1.08 1.20 1.06 1.02 .88
ATP 1.05 .98 1.11 .97 1.01 1.44 1.24
KLA/ATP 1.23 1.32 1.23 1.17 1.16 1.43 1.15
Pvrl3
KLA  ATP  ATP+KLA
 NM_021496 poliovirus receptor-related 3 (Pvrl3), transcript variant beta, mRNA [NM_021496] KLA .99 1.00 1.12 1.00 1.05 .97 1.05
ATP 1.04 1.01 1.01 .98 1.02 1.06 1.05
KLA/ATP 1.04 1.06 1.09 1.03 1.01 1.06 1.00
Pvrl4
KLA  ATP  ATP+KLA
 NM_027893 poliovirus receptor-related 4 (Pvrl4), transcript variant 1, mRNA [NM_027893] KLA 2.67 2.72 3.34 3.19 3.17 3.15 1.75
ATP 1.02 .89 .88 .85 .75 1.22 1.85
KLA/ATP 2.51 2.64 2.28 1.78 2.04 2.70 3.18
Rac1
KLA  ATP  ATP+KLA
 NM_009007 RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] KLA 1.02 1.01 1.02 .99 1.03 1.15 1.08
ATP .99 1.15 1.01 1.27 1.06 1.20 1.06
KLA/ATP 1.00 1.04 .88 1.16 .91 1.21 1.38
Rac2
KLA  ATP  ATP+KLA
 NM_009008 RAS-related C3 botulinum substrate 2 (Rac2), mRNA [NM_009008] KLA 1.55 1.68 1.86 2.15 3.36 3.59 3.74
ATP 1.13 1.16 .74 .99 .84 .91 1.66
KLA/ATP 1.59 1.71 1.19 1.56 1.21 1.60 3.48
Rac3
KLA  ATP  ATP+KLA
 NM_133223 RAS-related C3 botulinum substrate 3 (Rac3), mRNA [NM_133223] KLA 2.03 2.20 2.64 2.18 2.95 2.29 1.41
ATP 1.02 1.12 .94 1.42 1.16 .84 .87
KLA/ATP 2.30 2.32 1.57 2.55 1.75 1.47 1.61
Rhoa
KLA  ATP  ATP+KLA
 NM_016802 ras homolog gene family, member A (Rhoa), mRNA [NM_016802] KLA .93 1.00 1.07 .97 1.08 1.06 1.02
ATP .93 .88 .49 .61 .63 .78 1.05
KLA/ATP .94 .92 .59 .63 .61 .78 1.12
Smad2
KLA  ATP  ATP+KLA
 NM_010754 MAD homolog 2 (Drosophila) (Smad2), mRNA [NM_010754] KLA 1.05 1.08 1.04 1.17 1.40 1.43 1.59
ATP 1.01 1.02 1.16 1.14 1.15 1.32 1.34
KLA/ATP 1.00 .99 .97 1.09 1.40 1.14 1.40
Smad3
KLA  ATP  ATP+KLA
 NM_016769 MAD homolog 3 (Drosophila) (Smad3), mRNA [NM_016769] KLA .64 .60 .57 .64 .70 1.25 1.52
ATP 1.02 1.02 .84 1.21 2.42 .90 1.19
KLA/ATP .64 .60 .65 .66 1.29 1.26 2.26
Smad4
KLA  ATP  ATP+KLA
 NM_008540 MAD homolog 4 (Drosophila) (Smad4), mRNA [NM_008540] KLA 1.11 1.11 1.13 1.09 1.02 .98 1.08
ATP 1.00 1.04 .92 .76 1.67 1.44 .92
KLA/ATP 1.09 1.01 .87 .89 1.64 1.43 .99
Snai1
KLA  ATP  ATP+KLA
 NM_011427 snail homolog 1 (Drosophila) (Snai1), mRNA [NM_011427] KLA .94 1.01 .90 1.12 1.04 1.04 1.02
ATP 1.06 1.04 1.04 1.70 1.56 1.12 1.04
KLA/ATP 1.10 1.02 1.23 2.64 2.26 1.52 1.15
Snai2
KLA  ATP  ATP+KLA
 NM_011415 snail homolog 2 (Drosophila) (Snai2), mRNA [NM_011415] KLA 1.08 1.08 1.07 1.00 .98 1.00 1.11
ATP 1.02 .95 .96 1.04 .92 .99 .97
KLA/ATP 1.07 1.11 1.07 1.05 .93 1.07 .93
Sorbs1
KLA  ATP  ATP+KLA
 NM_178362 sorbin and SH3 domain containing 1 (Sorbs1), transcript variant 2, mRNA [NM_178362] KLA .92 .85 .90 .76 .93 .86 .86
ATP .96 1.02 .95 .73 .70 1.05 .79
KLA/ATP .86 .85 .93 .70 .74 1.25 1.40
Src
KLA  ATP  ATP+KLA
 NM_009271 Rous sarcoma oncogene (Src), transcript variant 1, mRNA [NM_009271] KLA 6.99 7.23 7.54 5.99 5.34 3.39 3.00
ATP 1.02 1.06 1.06 2.08 4.41 5.03 3.97
KLA/ATP 7.44 7.51 5.48 6.24 4.86 5.86 7.90
Ssx2ip
KLA  ATP  ATP+KLA
 NM_138744 synovial sarcoma, X breakpoint 2 interacting protein (Ssx2ip), mRNA [NM_138744] KLA .56 .52 .52 .52 .55 .57 .86
ATP 1.02 .95 .84 .70 .74 1.21 .86
KLA/ATP .55 .52 .55 .49 .65 1.04 .76
Tcf3
KLA  ATP  ATP+KLA
 NM_001079822 transcription factor 3 (Tcf3), transcript variant 1, mRNA [NM_001079822] KLA 1.03 .98 1.01 .98 .98 1.03 1.01
ATP 1.00 1.02 1.00 1.06 1.10 1.07 .99
KLA/ATP 1.07 .99 .97 1.05 1.05 1.11 .96
Tcf7
KLA  ATP  ATP+KLA
 NM_009331 transcription factor 7, T-cell specific (Tcf7), mRNA [NM_009331] KLA 1.00 1.01 1.03 1.00 .98 1.01 1.07
ATP .99 .98 1.02 1.03 1.03 1.00 1.01
KLA/ATP 1.00 1.03 1.04 1.02 1.04 1.02 1.00
Tcf7l2
KLA  ATP  ATP+KLA
 NM_009333 transcription factor 7-like 2, T-cell specific, HMG-box (Tcf7l2), mRNA [NM_009333] KLA 1.01 1.12 1.11 1.31 1.06 1.34 1.29
ATP 1.04 1.05 .94 1.06 .90 .81 .96
KLA/ATP 1.08 1.11 1.05 1.18 1.04 1.02 1.42
Tgfbr1
KLA  ATP  ATP+KLA
 NM_009370 transforming growth factor, beta receptor I (Tgfbr1), mRNA [NM_009370] KLA .73 .74 .59 .54 .52 .64 .84
ATP .99 1.12 .99 1.16 1.22 .84 .93
KLA/ATP .75 .78 .58 .64 .62 .59 .77
Tgfbr2
KLA  ATP  ATP+KLA
 AK090393 10 days pregnant adult female ovary and uterus cDNA, RIKEN full-length enriched library, clone:G630098D03 product:transforming growth factor, beta receptor II, full insert sequence. [AK090393] KLA .98 .89 1.00 .96 .94 1.00 .92
ATP .99 .99 .90 .94 .93 .96 1.02
KLA/ATP .92 .96 .98 .98 .98 .95 1.01
Tgfbr2
KLA  ATP  ATP+KLA
 NM_009371 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 1, mRNA [NM_009371] KLA .55 .50 .58 .50 .52 .55 .44
ATP .98 .75 .50 .32 .41 .29 .50
KLA/ATP .59 .45 .32 .23 .31 .27 .25
Tgfbr2
KLA  ATP  ATP+KLA
 NM_029575 transforming growth factor, beta receptor II (Tgfbr2), transcript variant 2, mRNA [NM_029575] KLA .95 .93 .99 .95 .88 1.02 .82
ATP .87 .93 .84 .84 .74 .72 1.00
KLA/ATP .89 .85 .83 .85 .76 .80 .79
Tjp1
KLA  ATP  ATP+KLA
 NM_009386 tight junction protein 1 (Tjp1), mRNA [NM_009386] KLA 1.00 1.03 1.07 1.00 1.03 1.03 1.09
ATP 1.01 .98 1.06 1.00 1.00 1.05 1.04
KLA/ATP .99 1.04 1.06 1.08 1.10 1.21 1.11
Vcl
KLA  ATP  ATP+KLA
 NM_009502 vinculin (Vcl), mRNA [NM_009502] KLA .88 .97 .87 .70 .73 .69 .70
ATP 1.07 1.25 1.00 1.24 .87 1.17 1.17
KLA/ATP .98 1.02 .72 .98 .58 .71 .88
Was
KLA  ATP  ATP+KLA
 NM_009515 Wiskott-Aldrich syndrome homolog (human) (Was), mRNA [NM_009515] KLA .66 .67 .64 .65 .88 1.08 1.09
ATP 1.08 1.11 .87 1.23 .77 .51 .90
KLA/ATP .76 .70 .44 .83 .49 .61 .91
Wasf1
KLA  ATP  ATP+KLA
 NM_031877 WASP family 1 (Wasf1), mRNA [NM_031877] KLA .75 .69 .77 .81 .69 .66 .54
ATP 1.01 .97 .93 .98 .70 .66 .97
KLA/ATP .75 .73 .80 .79 .73 .67 .56
Wasf2
KLA  ATP  ATP+KLA
 AK150140 bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:G530136J12 product:WAS protein family, member 2, full insert sequence [AK150140] KLA .58 .52 .52 .83 1.06 1.17 .91
ATP .97 .89 .93 .57 .72 .72 .86
KLA/ATP .55 .45 .56 .36 .45 .65 1.08
Wasf2
KLA  ATP  ATP+KLA
 NM_153423 WAS protein family, member 2 (Wasf2), mRNA [NM_153423] KLA .67 .75 .66 1.01 1.31 1.28 1.19
ATP 1.05 1.10 .82 .81 .82 .68 .92
KLA/ATP .75 .76 .73 .57 .61 .77 1.16
Wasf3
KLA  ATP  ATP+KLA
 NM_145155 WAS protein family, member 3 (Wasf3), mRNA [NM_145155] KLA .94 .95 1.06 .95 1.00 1.10 1.07
ATP .95 .96 .93 1.01 1.01 1.03 1.08
KLA/ATP 1.01 .91 .96 .95 .96 1.03 1.05
Wasl
KLA  ATP  ATP+KLA
 NM_028459 Wiskott-Aldrich syndrome-like (human) (Wasl), mRNA [NM_028459] KLA .88 .89 .96 .85 .97 1.08 1.14
ATP 1.08 .99 .71 .76 1.71 .91 .99
KLA/ATP .96 .84 .72 .84 1.51 .91 1.24
Yes1
KLA  ATP  ATP+KLA
 NM_009535 Yamaguchi sarcoma viral (v-yes) oncogene homolog 1 (Yes1), mRNA [NM_009535] KLA .99 1.14 .97 .99 .99 1.02 1.05
ATP 1.07 .98 1.00 1.09 .98 .99 1.00
KLA/ATP 1.04 1.04 .89 1.01 1.04 1.02 1.07